Karolinska Developments portföljbolag Umecrine Cognition säkrar ytterligare finansiering för vidareutveckling av golexanolon
March 28, 2023 02:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 28 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har tagit in ytterligare finansering för den fortsatta utvecklingen...
Karolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone
March 28, 2023 02:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – March 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has secured additional funding for the continued...
Karolinska Developments årsredovisning för 2022 har publicerats
March 24, 2023 03:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 24 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att årsredovisningen för 2022 har offentliggjorts. Årsredovisningen finns nu tillgänglig på...
Karolinska Development Annual Report 2022 published
March 24, 2023 03:00 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – March 24, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2022. The report is now available to download at...
Karolinska Developments portföljbolag AnaCardios grundare publicerar studie som stöder utveckling av AC01 för behandling av hjärtsvikt
March 14, 2023 08:28 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 14 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardios grundare, professor Lars Lund, har publicerat en studie inom hjärtsvikt...
Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01
March 14, 2023 08:28 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN March 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the founder of its portfolio company AnaCardio, Professor Lars Lund, has published an article...
Karolinska Developments portföljbolag Biosergen presenterar positiva resultat från en fas 1-studie av läkemedelskandidat mot systemisk svampinfektion
March 13, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 13 mars 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Biosergen presenterat positiva resultat från en klinisk fas 1-studie med...
Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection
March 13, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, Sweden, March 13, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Biosergen has presented positive results from a clinical phase 1 study of its...
Karolinska Developments portföljbolag Aprea Therapeutics säkrar finansiering om USD 5,5 miljoner
February 28, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 28 februari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har tagit in finansiering genom en garanterad nyemission...
Karolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million
February 28, 2023 11:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has closed an underwritten public offering of USD 5.5...